Introduction {#s01}
============

Mutations or deletion of the *PTEN* locus are common and associated with metastasis and resistance to therapeutic castration in prostate cancer ([@bib11]; [@bib13]; [@bib32]; [@bib17]). Genetic ablation of *PTEN* or expression of a dominant-negative mutant of PTEN in mouse prostate epithelial cells (PECs) induces prostatic intraepithelial neoplasia (PIN) with full penetrance ([@bib12]; [@bib36]; [@bib51]; [@bib49]).

Several studies have shown that the progression of *PTEN* loss--induced PINs is antagonized by cell senescence in mice ([@bib12]; [@bib2]; [@bib20]). Senescence is triggered in response to various stimuli ([@bib64]; [@bib18]), including the expression of oncogenes in untransformed cells (e.g., Ras^G12V^, E2F1, Raf, Mos, Cdc6, cyclin E, Stat5, and PML; [@bib57]; [@bib24]; [@bib46]; [@bib39]; [@bib18]). Oncogene-induced senescence (OIS), by permanently halting cell proliferation and promoting immune surveillance of premalignant lesions, is a barrier against cell transformation ([@bib8]; [@bib12]; [@bib29]). Accordingly, markers of senescence have been observed in premalignant lesions in various human tissues, including the prostate, but not in the corresponding tumors ([@bib12]; [@bib46]; [@bib15]; [@bib60]). Thus, escaping or avoiding OIS likely represents a critical step toward transformation.

The DNA damage response (DDR) pathway is a central regulator of OIS ([@bib7]; [@bib6]; [@bib39]; [@bib18]). Indeed, the expression of oncogenes has been shown to stimulate cell proliferation, causing replication stress and a robust activation of the DDR pathway ([@bib7]; [@bib6]), whereas inactivation of components of the DDR pathway bypasses OIS ([@bib19]; [@bib39]). Induction of the DDR stabilizes p53 through its phosphorylation by DDR kinases (ATR, ATM, DNA-PK, CHK1, and CHK2; [@bib65]; [@bib33]). p53 promotes OIS through transcriptional regulation of an array of genes, including p21, an inhibitor of cell cycle progression ([@bib47]).

*PTEN* loss--induced senescence (PICS) was also shown to be p53-dependent ([@bib12]), but as no hyperproliferation and DDR activation was observed ([@bib2]; [@bib4]), it was concluded that PICS is a new type of senescence ([@bib12]; [@bib18]; [@bib4]). Moreover, Di Mitri et al. reported that tumor-infiltrated GR-1--positive myeloid cells antagonize PICS and sustain tumor growth ([@bib20]).

To further characterize PICS in vivo, we analyzed PTEN^(i)pe−/−^ mice in which *PTEN* is selectively ablated in prostatic luminal cells at adulthood, via the tamoxifen (Tam)-dependent Cre-ER^T2^ system ([@bib51]). These mice develop slowly progressing PIN lesions with a highly reproducible kinetics. We took advantage of the strict temporal control of *PTEN* ablation in this model to characterize the fate of *PTEN*-deficient PECs. Our study reveals that *PTEN* ablation stimulates proliferation of PECs during several months, followed by a progressive growth arrest with characteristics of cell senescence. Importantly, we also show that proliferating *PTEN*-deficient PECs undergo replication stress and mount a DDR that stabilizes p53. However, as p53 is actively down-regulated at early time by Mdm2, cell senescence is delayed by several months.

Results {#s02}
=======

*PTEN*-deficient PECs actively proliferate to generate PINs prior to becoming senescent {#s03}
---------------------------------------------------------------------------------------

To study the consequences of *PTEN* loss in PECs of adult mice, we analyzed PTEN^(i)pe−/−^ and PTEN^pe+/+^ (control) mice over a period of 12 mo after *PTEN* ablation (Fig. S1 A). The prostate weight of PTEN^(i)pe−/−^ mice increased during the first 3 mo after *PTEN* ablation to reach twice that of control mice and remained stable for the following 9 mo ([Fig. 1 A](#fig1){ref-type="fig"}). In agreement with previous results ([@bib51]), the levels of pAKT S473 were enhanced in the prostate of PTEN^(i)pe−/−^ mice, and \>75% of the glands in the dorsolateral prostate (DLP) contained PINs between 1 and 12 mo (Fig. S1, B--E). The mitotic index of PECs was approximately four- to fivefold higher in PTEN^(i)pe−/−^ mice than in control mice between 1 and 3 mo, but progressively decreased at a later time ([Fig. 1 B](#fig1){ref-type="fig"}). No terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive apoptotic cells were observed in PECs of PTEN^(i)pe−/−^ mice (Fig. S1 F), but transcript levels of the negative regulators of cell cycle progression *Cdkn1a* (*p21*) and *Cdkn2a* (*p16* and *p19ARF*) were markedly increased at 5 mo and 12 mo ([Fig. 1 C](#fig1){ref-type="fig"}). In contrast, transcript levels of *p16* and *p19ARF* were similar in PTEN^(i)pe−/−^ and control mice at 1 mo and slightly increased at 2 mo, whereas those of *p21* were increased by 2-fold at 1 mo and by 10-fold at 2 mo ([Fig. 1 C](#fig1){ref-type="fig"}). From 2 to 12 mo, \>95% PIN cells in DLP of PTEN^(i)pe−/−^ mice displayed nuclear foci of phosphorylated HP1γ (pHP1γ; [Fig. 1 D](#fig1){ref-type="fig"} and Fig. S2), indicative of senescence-associated heterochromatin foci (SAHF; [@bib1]). At 12 mo, most of PIN cells in PTEN^(i)pe−/−^ mice exhibited staining for senescence-associated β-galactosidase (SA-βGal), a well-accepted marker of cell senescence ([@bib21]; [@bib14]), and ∼20--50% of PIN cells were SA-βGal positive at 2 and 5 mo, respectively ([Fig. 1 E](#fig1){ref-type="fig"}). In contrast, at 1 mo, only ∼7% of PEC were pHP1γ-positive in PTEN^(i)pe−/−^ mice, and almost no SA-βGal staining was observed. Transcript levels of several members of the senescence-associated secretory phenotype (SASP; e.g., *IL-1α*, *IL-1β*, *M-CSF*, and *TNFα*) ([@bib50]) were increased by 4- to 15-fold at 2 and 5 mo in the prostate of PTEN^(i)pe−/−^ mice, whereas their levels were similar in control and PTEN^(i)pe−/−^ mice at 1 mo ([Fig. 2](#fig2){ref-type="fig"}). Thus, *PTEN* deficiency stimulates the proliferation of PECs within 1 mo to form PINs, which become progressively senescent within the following months.

![**Characterization of prostate tumors in PTEN^(i)pe−/−^ mice. (A)** Prostate weight (normalized over body weight) in PTEN^(i)pe−/−^ and control mice over 12 mo after *PTEN* ablation. Values are mean of four to six mice ± SEM. **(B)** Proliferation index (percentage of Ki67-positive epithelial cells) of DLP in PTEN^(i)pe−/−^ and control mice over 12 mo after gene ablation. Values are mean of four to eight mice ± SEM. Data are representative of two experiments. **(C)** Relative transcript levels of *Cdkn1a* (*p21*) and *Cdkn2a* (*p16* and *p19ARF*) in the prostate of PTEN^(i)pe−/−^ and control mice over 12 mo after gene ablation. Values are mean from four to eight mice ± SEM. **(D)** Quantification of pHP1γ-positive cells in DLP epithelium of PTEN^(i)pe−/−^ and control mice over 12 mo after gene ablation. Values are mean from four to six mice ± SEM. **(E)** Representative SA-βGal staining (blue) of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed at indicated time points after gene ablation. Pink, hematoxylin staining. Bars, 250 µm. Four to six mice were analyzed for each time point. ns, not significant, P value ≥ 0.05; \*, P value \< 0.05; \*\*, P value \< 0.01; \*\*\*, P value \< 0.001; \*\*\*\*, P value \< 0.0001.](JEM_20171207_Fig1){#fig1}

![**Characterization of the senescence-associated secretory phenotype in the prostate of PTEN^(i)pe−/−^ mice. (A--D)** Relative transcript levels of *Il-1α* (A), *Il-1β* (B), *M-CSF* (C), and *TNFα* (D) in the prostate of PTEN^(i)pe−/−^ and control mice over 5 mo after gene ablation. Values are mean of four to six mice ± SEM. Data are representative of three experiments. ns, not significant. \*, P value \< 0.05; \*\*, P value \< 0.01; \*\*\*\*, P value \< 0.0001.](JEM_20171207_Fig2){#fig2}

*PTEN* deficiency in PECs induces replication stress {#s04}
----------------------------------------------------

Because DDR is an inducer of OIS ([@bib7]; [@bib19]; [@bib39]), we investigated the levels of phosphohistone H2AX S139 (γH2AX), a faithful marker of DDR activation ([@bib54]; [@bib38]). Western blot analysis showed increased levels of γH2AX in DLP extracts of PTEN^(i)pe−/−^ mice at 1 mo (Fig. S3 A), and immunohistological analyses revealed that most PECs in DLP of PTEN^(i)pe−/−^ mice present a nuclear staining of γH2AX, whereas no staining was observed in the prostatic epithelium of age-matched control mice ([Fig. 3 A](#fig3){ref-type="fig"}). Although most cells displayed numerous small nuclear foci, ∼5% of the cells exhibited a very intense γH2AX nuclear staining (γH2AX-high), and often, no individual γH2AX foci could be distinguished in these cells ([Fig. 3 A](#fig3){ref-type="fig"}). Importantly, γH2AX-high PECs stained positive for the proliferation marker PCNA (Fig. S3 B), and individual γH2AX foci colocalized with foci of PCNA ([Fig. 3 B](#fig3){ref-type="fig"}). In contrast, no γH2AX foci were observed in PCNA-positive PECs of age-matched control mice. Therefore, in γH2AX-high PECs, γH2AX foci are localized at the vicinity or at the site of DNA replication, which is characteristic of replication stress ([@bib61]). In addition, labeling of DNA-replicating cells with BrdU revealed that all γH2AX-high PECs were BrdU-positive in PTEN^(i)pe−/−^ mice ([Fig. 3 C](#fig3){ref-type="fig"}). Moreover, at 1 and 2 mo, PECs of PTEN^(i)pe−/−^ mice displayed numerous nuclear foci of RPA32, a subunit of the single-stranded genomic DNA (ssDNA) complex replication protein A (RPA) that coats stretches of ssDNA in replication stress ([@bib9]; [@bib10]), although such foci were rarely observed in prostatic epithelial cells of age-matched control mice ([Fig. 4 A](#fig4){ref-type="fig"} and not depicted). RPA phosphorylation at various sites occurs at stalled replication forks, and DNA double strand breaks (DSB) produced from stalled DNA replication induce phosphorylation of RPA32 at S4 and S8 ([@bib34]; [@bib58]). Interestingly, at 1 mo, many PEC nuclei of PTEN^(i)pe−/−^ mice contained high levels of S4/S8 phosphorylated RPA32 ([Fig. 4 B](#fig4){ref-type="fig"}), indicating that DSB follow replication fork stalling. Numerous nuclear foci of ATR (Ataxia telangiectasia and Rad3-related) and 53BP1 (p53-binding protein 1) were also observed in PECs of PTEN^(i)pe−/−^ mice, whereas none were observed in PECs of age-matched control mice ([Fig. 4, C and D](#fig4){ref-type="fig"}), further supporting activation of DDR signaling ([@bib16]; [@bib37]). Together these results show that replication stress-mediated DDR signaling is induced in proliferating *PTEN*-deficient PECs. In agreement with the DDR mediating senescence induction, discrete foci of γH2AX were present in most PIN cells of PTEN^(i)pe−/−^ mice at 5 mo (Fig. S3 C), similar to long term γH2AX foci observed in OIS ([@bib52]).

![**Characterization of replication stress in *PTEN*-deficient PECs. (A)** Representative γH2AX immunofluorescence staining (red) of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed 1 mo after gene ablation. Yellow arrow, example of γH2AX-high staining; white arrow, example of γH2AX-low staining. **(B)** Representative immunofluorescence staining of γH2AX (green) and PCNA (red) of a DLP section of a PTEN^(i)pe−/−^ and of a control mouse sacrificed 1 mo after gene ablation. **(C)** Representative immunofluorescence staining of γH2AX (red) and BrdU (green) of a DLP section of a PTEN^(i)pe−/−^ mouse sacrificed 1 mo after gene ablation. Blue, Dapi. Bars: main images, 10 µm; insets, 5 µm. Four PTEN^(i)pe−/−^ mice and four control mice were analyzed.](JEM_20171207_Fig3){#fig3}

![**Immunodetection of DDR markers in *PTEN*-deficient PECs. (A)** Representative immunofluorescence staining of RPA32 (red) of DLP sections of PTEN^(i)pe−/−^ or control mice sacrificed 2 mo after gene ablation. **(B)** Representative RPA32 pS4/S8 immunofluorescence staining (red) of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed 1 mo after gene ablation. **(C)** Representative ATR immunofluorescence staining (red) of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed 2 mo after gene ablation. **(D)** Representative immunofluorescence staining of 53BP1 (red) of DLP sections of PTEN^(i)pe−/−^ or control mice sacrificed 2 mo after gene ablation. Blue, Dapi. Bars: main images, 20 µm; insets, 5 µm. Four PTEN^(i)pe−/−^ mice and four control mice were analyzed. A quantification of immunolabeled epithelial cells is shown in each panel. \*, P value \< 0.05; \*\*, P value \< 0.01; \*\*\*, P value \< 0.001.](JEM_20171207_Fig4){#fig4}

DDR stabilizes p53 in proliferating PECs of PTEN^(i)pe−/−^ mice. {#s05}
----------------------------------------------------------------

Because p53 can be stabilized by the DDR ([@bib44]), we immunodetected p53. Nuclear accumulation of p53 was observed in \>90% PECs of PTEN^(i)pe−/−^ mice at 2 mo, whereas almost all PECs displayed nuclear p53 at 5 and 12 mo ([Fig. 5 A](#fig5){ref-type="fig"} and Fig. S4 A). No p53-positive nuclei were detected in prostate epithelium of control mice at any time point. Therefore, *PTEN* ablation induced nuclear accumulation of p53 in PECs within 2 mo and up to 12 mo. In contrast, at 1 mo, only ∼6% of PECs were p53-positive in PTEN^(i)pe−/−^ mice ([Fig. 5 A](#fig5){ref-type="fig"} and Fig. S4 A), and most of them were Ki67- and BrdU-positive ([Fig. 5 B](#fig5){ref-type="fig"} and Fig. S4 B). This is in agreement with the slightly increased expression of the p53-target gene p21 at 1 mo ([Fig. 1 C](#fig1){ref-type="fig"}) and shows that activation of p53 signaling precedes senescence.

![**Characterization of p53-positive *PTEN*-deficient PECs. (A)** Representative p53 immunofluorescence staining (red) of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed at indicated time points after gene ablation. White arrow, example of a stained nucleus at 1 mo. **(B)** Representative BrdU (red) and p53 (green) immunofluorescence staining of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed 1 mo after gene ablation. White arrow, example of a double-stained nucleus. **(C)** Representative p53 pS15 (green) and Ki67 (red) immunofluorescence staining of DLP sections of PTEN^(i)pe−/−^ and control mice sacrificed 1 mo after gene ablation. White arrow, example of a double-stained nucleus. Blue, Dapi. Bars: 25 µm (A); 10 µm (B and C). Four PTEN^(i)pe−/−^ mice and four control mice were analyzed.](JEM_20171207_Fig5){#fig5}

Activation of the DDR increases p53 stability and its transcriptional activity through phosphorylation of its serine 15 ([@bib44]). p53 pS15 nuclear staining was observed in ∼5% PECs of PTEN^(i)pe−/−^ mice at 1 mo, and these cells also stained for the proliferation marker Ki67 ([Fig. 5 C](#fig5){ref-type="fig"}). Therefore, p53 is stabilized in proliferating PECs of PTEN^(i)pe−/−^ mice by a DDR-mediated pathway.

p53 stabilization is counteracted by the protein kinase B (AKT)--Mdm2 axis. {#s06}
---------------------------------------------------------------------------

To investigate the role of p53 in the control of senescence induced by *PTEN* loss, we administered Tam to 8-wk-old PSA-CreER^T2^ mice bearing LoxP-flanked *PTEN* and *p53* alleles to generate PTEN/p53^(i)pe−/−^ mice in which both *PTEN* and *p53* are ablated in PECs at adulthood.

As expected, no nuclear staining for p53 was observed in PECs of PTEN/p53^(i)pe−/−^ mice (Fig. S4, C and D). At 1 and 2 mo, the prostate weights were similar in PTEN/p53^(i)pe−/−^ and in PTEN^(i)pe−/−^ mice ([Fig. 6 A](#fig6){ref-type="fig"}). The mitotic index of PECs was similar in PTEN/p53^(i)pe−/−^ and PTEN^(i)pe−/−^ mice at 1 mo, but was higher in PTEN/p53^(i)pe−/−^ mice than in PTEN^(i)pe−/−^ at 2, 5, and 6 mo ([Fig. 6 B](#fig6){ref-type="fig"}). At 5 and 6 mo, the prostate weight was threefold higher in PTEN/p53^(i)pe−/−^ than in PTEN^(i)pe−/−^ mice ([Fig. 6 A](#fig6){ref-type="fig"}). Whereas PIN lesions in DLP were similar in PTEN/p53^(i)pe−/−^ and in PTEN^(i)pe−/−^ mice at 1 and 2 mo, they were more severe in PTEN/p53^(i)pe−/−^ mice than in PTEN^(i)pe−/−^ mice at 5 and 6 mo with, in some cases, a loss of prostate epithelium architecture (compare [Fig. 6 C](#fig6){ref-type="fig"} and Fig. S1 C). Therefore, *p53* ablation does not affect early stimulation of *PTEN*-null PEC proliferation and PIN formation, but impairs their subsequent growth arrest.

![**Prostate tumor evolution in PTEN/p53^(i)pe−/−^ mice. (A)** Evolution of normalized prostate weight (prostate weight over body weight) in PTEN^(i)pe−/−^ and PTEN/p53^(i)pe−/−^ mice over 6 mo after gene ablation. Values are mean from of four to eight mice ± SEM. **(B)** Proliferation index (percentage of Ki67-positive cells) of DLP epithelial cells in PTEN^(i)pe−/−^ and PTEN/p53^(i)pe−/−^ mice over 6 mo after gene ablation. Values are mean from of four to eight mice ± SEM. **(C)** Representative views of DLP sections of PTEN/p53^(i)pe−/−^ and control mice sacrificed at 1, 2, and 5 mo after gene ablation and of DLP sections of PTEN/p53^(i)pe−/−^ mice with large tumors, sacrificed 6 mo after gene ablation. Sections were stained with H&E. Bars, 125 µm. Four to eight PTEN/p53^(i)pe−/−^ mice per time point and eight control mice were analyzed. ns, not significant, P value ≥ 0.05; \*, P value \< 0.05; \*\*, P value \< 0.01; \*\*\*, P value \< 0.001; \*\*\*\*, P value \< 0.0001.](JEM_20171207_Fig6){#fig6}

Di Mitri et al. reported that GR1-positive myeloid cells infiltrate the prostate of PTEN^pe−/−^ mice and secrete the cytokine IL-1RA, an antagonist of IL-1R, which opposes PICS in a paracrine fashion ([@bib20]). FACS analysis of dissociated prostates of PTEN^(i)pe−/−^ mice revealed that GR-1--positive myeloid cells represent ∼2.5--3% of all prostatic cells at 2 and 5 mo after *PTEN* ablation, but \<0.07% at 1 mo in both in PTEN^(i)pe−/−^ and control mice ([Fig. 7 A](#fig7){ref-type="fig"}). Moreover, the transcript levels of the marker of the myeloid lineage *CD11b*, and of *Ly6g* and *Ly6c*, the two GR-1 variants, were increased in PTEN^(i)pe−/−^ mice at 2 and 5 mo, but not at 1 mo ([Fig. 7, B--D](#fig7){ref-type="fig"}). In agreement with these results, the transcript levels of *IL-1rn*, coding for IL-1RA protein, were markedly increased at 2 and 5 mo in the prostate PTEN^(i)pe−/−^ mice, whereas they were similar in control and PTEN^(i)pe−/−^ mice at 1 mo ([Fig. 7 E](#fig7){ref-type="fig"}). Therefore, IL-1RA--producing GR-1--positive cells cannot account for the delay of PEC senescence entry induced by *PTEN* ablation.

![**Characterization of GR1-positive myeloid cells and *IL1rn* expression during PIN evolution in PTEN^(i)pe−/−^ mice. (A)** FACS quantification of GR1-positive myeloid (CD11b-positive) cells in the prostate of PTEN^(i)pe−/−^ and control mice (percentage of the total cells in dissociated prostates) sacrificed at the indicated time points after gene ablation. **(B--E)** Values are mean of three to six mice ± SEM. Relative transcript levels of *CD11b* (B), *Ly6g* (C), *Ly6c* (D) and *IL-1rn* (E) in the prostate of PTEN^(i)pe−/−^ and control mice sacrificed at indicated time points after gene ablation. Values are mean of four to ten mice ± SEM. ns, not significant, P value ≥ 0.05; \*\*, P value \< 0.01; \*\*\*\*, P value \< 0.0001.](JEM_20171207_Fig7){#fig7}

In unstressed cells, p53 is maintained at low level by proteasomal degradation through mouse double-minute 2 (Mdm2)-mediated polyubiquitylation ([@bib53]). Stabilization of p53 involves the dissociation of p53 from Mdm2 through modifications of p53, including phosphorylation by DDR kinases ATR or ATM. Once stabilized, p53 translocates to the nucleus, whereas Mdm2 is submitted to proteasomal degradation. At 1 mo, high levels of Mdm2 were present in the nuclei of pAKT S473--positive PECs of PTEN^(i)pe−/−^ mice ([Fig. 8 A](#fig8){ref-type="fig"}). Moreover, Mdm2-positive cells were p53-negative, and p53 was only detected in Mdm2-low cells ([Fig. 8 B](#fig8){ref-type="fig"}). To demonstrate that Mdm2 was involved in p53 degradation at early time, PTEN^(i)pe−/−^ mice were treated with Nutlin-3, an inhibitor of Mdm2--p53 interaction ([@bib59]) 1 mo after *PTEN* ablation. Our results show that Nutlin-3a treatment increases p53 protein levels in prostatic epithelial cells and enhances the transcript levels of p53 target gene *p21* ([Fig. 8, C--E](#fig8){ref-type="fig"}). Thus, low p53 levels at early time result from Mdm2-mediated p53 degradation.

![**Characterization of Mdm2 expression in the prostate of PTEN^(i)pe−/−^ mice. (A)** Representative pAKT S473 (green) and Mdm2 (red) immunofluorescence staining of DLP sections of a PTEN^(i)pe−/−^ mouse sacrificed 1 mo after gene ablation. Blue, Dapi. Four mice were analyzed. **(B)** Representative p53 (green) and Mdm2 immunofluorescence staining (red) of DLP sections of a PTEN^(i)pe−/−^ mouse sacrificed 1 mo after gene ablation. Four mice were analyzed. **(C)** Representative p53 immunofluorescence staining (red) of DLP sections of PTEN^(i)pe−/−^ mice treated with vehicle- and Nutlin-3 1 mo after gene ablation (*n* = 3 for each condition). Blue, Dapi. Bars: 20 µm (A and C); 10 µm (B). Data are representative of two experiments; *n* = 3 vehicle and *n* = 3 Nutlin-treated PTEN^(i)pe−/−^ mice. **(D)** Quantification of p53 positive epithelial cells in PINs of PTEN^(i)pe−/−^ mice treated 1 mo after gene ablation with vehicle and Nutlin-3. Data are cumulative of two experiments; *n* = 3 for each group. Unpaired-*t* test. \*\*\*, P value \< 0.001. **(E)** Relative transcript levels of *p21* in the DLP and AP of vehicle- and Nutlin-3 treated PTEN^(i)pe−/−^ mice. *n* = 7 vehicle and *n* = 8 Nutlin-3 treated PTEN^(i)pe−/−^ mice. Unpaired-*t* test. \*\*, P value \<0.01.](JEM_20171207_Fig8){#fig8}

Because AKT can phosphorylate Mdm2 at several serine residues (S166 and S186 in human, equivalent to S163 and S183, in mouse), inducing its nuclear translocation and accumulation ([@bib22]; [@bib62]), and increasing both its association and E3 ligase activity toward p53 ([@bib3]; [@bib42]; [@bib48]), AKT might promote Mdm2-mediated p53 proteasomal degradation in PECs of PTEN^(i)pe−/−^ mice. Importantly, most nuclei of PECs were Mdm2 pS163--positive at 1 mo, whereas Mdm2 pS163 was not immunodetected in normal prostate epithelium of PTEN^(i)pe−/−^ mice and of control mice ([Fig. 9 A](#fig9){ref-type="fig"} and not depicted). The level of Mdm2 pS163 decreased, however, between 1 and 2 mo, while p53 increased and was detected in most cells at 5 mo, whereas Mdm2 pS163 was detected no more ([Fig. 9 A](#fig9){ref-type="fig"} and [Fig. 5 A](#fig5){ref-type="fig"}). Moreover, because Casein Kinase I (CKI) family members have been shown to phosphorylate N-terminal sites of p53 and to decrease p53 affinity to Mdm2, and because phosphorylation of Mdm2 by CKIδ leads to Mdm2 degradation and p53 expression ([@bib31]), we determined their transcript levels in *PTEN*-deficient PINs at various time points. Interestingly, the transcript levels of *CKIα*, -*δ*, -*γ*, and -*ε* were induced 3 and 5 mo after gene invalidation, and at 5 mo, the transcript levels of *CKIε* correlated with *p21* levels ([Fig. 9, B and C](#fig9){ref-type="fig"}; and Fig. S5).

![**Immunodetection of Mdm2 pS163 and quantification of *CKIε* and *p21* transcript levels in DLP of PTEN^(i)pe-/-^ mice. (A)** Representative Mdm2 pS163 (red) immunofluorescence staining of DLP sections of control and PTEN^(i)pe−/−^ mice sacrificed at the indicated time after gene ablation. Blue, Dapi. Bars: main images, 40 µm; insets, 10 µm. Data are representative of three experiments with *n* = 3 mice per time point and two prostate sections per mouse. **(B)** Transcript levels of *CKIε* in the DLP and AP of PTEN^(i)pe−/−^ and control mice at the indicated time points. *n* = 3 for control mice at 5 mo and *n* = 4, *n* = 4, *n* = 4, *n* = 3, and *n* = 8 for PTEN^(i)pe−/−^ mice at 1, 2, 3, and 5 mo after gene ablation, respectively. Bars represent the mean ± SEM. One way ANOVA. ns; not significant; \*\*, P \< 0.01; \*\*\*, P \< 0.001. **(C)** Correlation between *p21* and *CKI1ε* transcript levels in the prostate of PTEN^(i)pe−/−^ mice 5 mo after *PTEN* ablation.](JEM_20171207_Fig9){#fig9}

Thus, as DNA damage has been shown to induce the interaction between Mdm2 and CKI ([@bib27]), it is likely that 3 mo after *PTEN* ablation, CKI-mediated Mdm2 degradation, and/or decreased binding of Mdm2 to p53 overcomes early Mdm2 activation and contributes to p53 stabilization.

Discussion {#s07}
==========

We show here that *PTEN* ablation in PECs of adult mice induces PINs formation, the progression of which is antagonized by a cell senescence barrier, in agreement with previous studies ([@bib12]; [@bib20]). Because PTEN knock-down in cultured cells was shown to induce a rapid senescence state in the absence of proliferation and DDR, in contrast to OIS ([@bib2]; [@bib4]), it was proposed that PICS is a new type of senescence. Moreover, it was shown that PICS is antagonized by IL-1RA secreted by infiltrated GR1-positive myeloid cells, allowing proliferation of a subset of *PTEN*-deficient PECs and, thereby, PIN formation ([@bib2]; [@bib20]).

We demonstrate here that GR1-positive cells and IL-1RN are not present in the prostate 1 mo after *PTEN* ablation in PTEN^(i)pe−/−^ mice and, thus, cannot contribute to the high proliferation rate and the absence of senescence markers at this stage. Therefore, we conclude that the first temporal consequence of *PTEN* ablation in mouse PECs is to increase their rate of proliferation, allowing PIN formation in most prostate ducts within 1 mo. Signs of senescence are observed only later, after several weeks of active proliferation.

Unlike previous studies ([@bib2]; [@bib4]), *PTEN* ablation in PECs induced γH2AX nuclear foci, clearly reflecting activation of the DDR. Our results are in agreement with a previous study showing that PTEN knock-down in human-immortalized fibroblasts induces cell senescence with accumulation of γH2AX foci ([@bib30]). Importantly, proliferating PECs in PTEN^(i)pe−/−^ mice displayed a very strong γH2AX staining, with numerous intense foci, and presented characteristics of replication stress, including accumulation of foci of RPA32 and RPA32 pS4/S8, as well as ATR, the DDR kinase activated by replication stress and a major effector of replication stress--mediated DDR ([@bib43]).

ATR can phosphorylate p53 S15 directly or via activation of CHK1 ([@bib43]), and our results show that actively proliferating cells exhibit a nuclear staining for p53 pS15 and that p53 mainly accumulates in Ki67-positive and BrdU-positive PECs. Therefore, p53 is stabilized by replication stress--mediated DDR activation in *PTEN*-deficient PECs, and replication stress--mediated p53 activation contributes to trigger senescence, as in OIS ([@bib7]; [@bib6]).

In addition, we show that Mdm2 accumulates in the nuclei of AKT pS473--positive PECs at 1 mo and that nuclear Mdm2 is phosphorylated at S163. It is well documented that Mdm2 can be phosphorylated at S163 by AKT, resulting in its translocation in the nucleus, while it increases its E3-ligase activity toward p53 and thus down-regulates p53 ([@bib41]; [@bib42]; [@bib48]; [@bib22]; [@bib23]). It has been shown that *PTEN* ablation in mouse cells and tissue results in a dramatic decrease of p53 expression ([@bib25]), and pharmacological inhibition of PI3K prevents p53 activation by DNA damage ([@bib5]). Moreover, activation of AKT by Her2 in breast cancer cells increases Mdm2-mediated p53 degradation via AKT-mediated Mdm2 phosphorylation on S163 ([@bib66]). Importantly, we show that early p53 degradation in *PTEN*-deficient PECs is mediated by Mdm2 and provide evidence that CKI contributes to p53 stabilization at later time. We thus propose that *PTEN* loss has two simultaneous and opposed consequences. Besides initiating a senescence program through replication stress mediated activation of the DDR and p53 stabilization, AKT activation induced by *PTEN* ablation contributes to delay senescence via enhanced Mdm2-mediated p53 degradation.

An important characteristic of our mouse model is the possibility to strictly control the time of floxed genes ablation by induction of the CreER^T2^ recombinase activity. In other models, *PTEN* ablation occurs in the undifferentiated prostate of young mice ([@bib12]; [@bib2]), because of the early activity of the Pb-4 promoter (in the prostate bud of the newborn) that drives the expression of a constitutively active Cre recombinase ([@bib63]). As we induced Cre-mediated recombination selectively in luminal prostatic epithelial cells after puberty, *PTEN* was ablated in a fully developed prostate and well-differentiated PECs. It was shown that PIN development is accelerated when *PTEN* is ablated before puberty ([@bib36]). Thus, the lower proliferation rate of PECs in our model, which reaches a maximum of ∼10%, although it reaches ∼40% in previously studied models ([@bib12]; [@bib2]), might contribute to the slow establishment of cell senescence, as replication stress might be less intense.

Our results diverge from several published studies on PICS. The discrepancy between our observations made in vivo in epithelial cells and in vitro results obtained in nonepithelial cells ([@bib2]; [@bib4]) might result from the obvious growth conditions differences. Indeed, in vitro cell culture conditions induce cellular stress, because partial O~2~ pressure is much higher in culture medium than in tissues, and because high levels of growth factors push the cells to actively proliferate ([@bib56]). Thus, cells in culture might induce pathways to cope with such stress conditions. In any event, our data highlight that in vitro data on senescence should not be extrapolated to in vivo situations.

As we demonstrate here that *PTEN* loss--induced cell senescence in prostate epithelial cells is mediated at least in part by replication stress after a phase of enhanced proliferation in vivo, this type of senescence resembles other types of senescence, in particular OIS, in contrast to previous conclusions drawn from others ([@bib2]). Thus, approaches for cancer prevention and therapy based on PICS induction are at risk, because replication stress induced by *PTEN* loss might result in an accumulation of mutations, including of *p53*, before p53 is stabilized and senescence initiated, and/or in senescent cells, leading to senescence escape and formation of adenocarcinoma. Supporting this idea, *p53* mutations cooccur with *PTEN* mutations in a high proportion of advanced prostate tumors ([@bib12]; [@bib35]; [@bib40]).

In contrast, selective inhibitors of AKT or of Mdm2-p53 interaction might enforce senescence and prevent or delay prostate cancer progression. However, the safest approach remains probably the elimination of senescent cells.

Materials and methods {#s08}
=====================

Mouse care {#s09}
----------

Mice were maintained in a temperature- and humidity-controlled animal facility with a 12 h light/dark cycle. Breeding and maintenance of mice were performed in the accredited IGBMC/ICS animal house (C67-2018-37), in compliance with French and EU regulations on the use of laboratory animals for research, under the supervision of D. Metzger who holds animal experimentation authorizations from the French Ministry of Agriculture and Fisheries (Nos. 67-209 and A 67-227). All animal experiments were approved by the Ethical committee Com'Eth (Comité d'Ethique pour l'Expérimentation Animale, Strasbourg, France). Animals were euthanized with carbon dioxide and cervical dislocation, and tissues were immediately collected, weighed and frozen in liquid nitrogen, or processed for biochemical and histological analysis.

Generation of mouse cohorts {#s10}
---------------------------

PTEN^(i)pe−/−^ mice were generated as described ([@bib51]). In brief, mice carrying one copy of the PSA-Cre-ER^T2^ transgene, expressing the Tam-inducible Cre-ER^T2^ recombinase in prostate epithelium under the control of the human PSA promoter, were crossed with mice carrying LoxP-flanked (floxed) alleles of *PTEN* (L2 allele; a gift from T. Mak, Campbell Family Institute for Breast Cancer Research, Toronto, Canada, and A Suzuki, Akita University School of Medicine, Akita, Japan) to generate PSA-Cre-ER^T2(tg/0)^/PTEN^L2/L2^ (tg, transgenic) and PSA-Cre-ER^T2(0/0)^/PTEN^L2/L2^ mice. PTEN/p53^(i)pe−/−^ mice were generated by intercrossing PSA-Cre-ER^T2(tg/0)^/PTEN^L2/L2^ mice with p53^L2/L2^ mice carrying floxed alleles of *p53* (a gift of A. Berns, The Netherlands Cancer Institute, Amsterdam, Netherlands; [@bib28]) to generate PSA-Cre-ER^T2(tg/0)^/PTEN^L2/L2^/p53^L2/L2^ and PSA-Cre-ER^T2(0/0)^/PTEN^L2/L2^/p53^L2/L2^ mice. Gene ablation was induced by intraperitoneal injection of Tam performed daily for 5 d (1 mg/mouse) to 8- to 10-wk-old mice, as described (Fig. S1 A; [@bib45]), to generate mutant PTEN^(i)pe−/−^ and PTEN/p53^(i)pe−/−^ mice. Respective control mice (PTEN^pe+/+^ and PTEN/p53^pe+/+^) did not bear the PSA-Cre-ER^T2^ transgene (pe, prostate epithelium; (i), induced).

PSA-Cre-ER^T2^, PTEN^L2/L2^, and p53^L2/L2^ mice were backcrossed on C57BL/6 mice for more than eight generations before intercrossing. Mice were genotyped by PCR performed on genomic DNA isolated from ear biopsies, using the DirectPCR extraction kit (102-T; Viagen) and primers as described ([@bib28]; [@bib51]).

Treatment of mice {#s11}
-----------------

Control and PTEN^(i)pe−/−^ mice were administered i.p. with 5-bromo-2\'-deoxyuridine (BrdU, Sigma-Aldrich) at 50 mg/kg in 100 µl of sterile saline solution (0.9% NaCl), 3 h before sacrifice. 1 mo after gene ablation, PTEN^pe−/−^ mice were treated (i.p.) with Nutlin-3 (daily 100 mg/kg; AdooQ Biosciences) or vehicle for 2 d and sacrificed 4 h after the last administration.

Histological analysis {#s12}
---------------------

Prostate tissue samples were immediately fixed in ice-cold 4% formaldehyde supplemented with 1 tablet/10 ml of PhoSTOP (04 906 837 001; Roche). Prostate samples were embedded in paraffin, and 5-µm serial sections were cut. For histopathological analyses, paraffin sections were stained with H&E. For immunofluorescence staining, sections were processed as previously described ([@bib51]), except that sections were incubated over night with primary antibodies diluted 1:200, unless indicated. Primary antibody used for immunofluorescence were directed against AKT pS473 (4060; Cell Signaling Technology), γH2AX (05-636; EMD Millipore; 1:600), p53 (CM5; Vector Labs), p53 pS15 (12571; Cell Signaling Technology), pHP1γ (2600; Cell Signaling Technology), RPA32 (GTX113004; Tebu-Bio), RPA32 pS4/S8 (A300-245A; Bethyl Laboratories), ATR (2790; Cell Signaling Technology), Ki67 (M7248; Dako), BrdU (600-401-C29; Rockland), ATM pS1966 (200-301-400; Rockland), Mdm2 (sc-965; Santa Cruz Biotechnology), Mdm2 pS166 (human)/pS163 (mouse; 3521; Cell Signaling Technology), PCNA (ab2426; AbCam), 53BP1 (NB100-305; Novus Biologicals). Secondary antibodies (CY3 AffiniPure goat anti--rabbit IgG \[H+L\], CY3 AffiniPure goat anti--mouse IgG \[H+L\], CY5 AffiniPure goat anti--mouse IgG \[H+L\], and CY5 AffiniPure donkey anti--rabbit IgG \[H+L\]) were from Jackson Immunoresearch.

SA-βGal staining {#s13}
----------------

10-μm frozen prostate sections were cut, fixed in 2% formaldehyde and 0.2% glutaraldehyde, stained in 100 mM K~3~Fe(CN)~6~, 100 mM K~4~Fe(CN)~6~, 2 mM MgCl~2~, 150 mM NaCl, citric acid phosphate buffer (0.2 M Na~2~HPO~4~ and 0.1 M Citric acid), and 1 mg/ml X-gal (Roche) for 6 h and counterstained in hematoxylin ([@bib21]).

TUNEL assays {#s14}
------------

10-μm paraffin-embedded prostate sections were cut and stained with TUNEL kit (11684817910; In Situ Cell Death Detection kit; Roche) following manufacturer's instructions.

Microscope image acquisition {#s15}
----------------------------

Microscopic analyses were performed at 21°C using a Leica Microsystems DM4000B with the following objectives: 10×, N Plan, dry, numerical aperture (NA): 0.25; 20×, HC Plan Apo dry, NA: 0.7; 40×, N Plan, dry, NA: 0.65; 63×, HCX Plan Apo, oil immersion, NA: 1.32--0.6; and 100, HCX PL Fluotar, oil immersion, NA: 1.30--0.6. Images were acquired with a 12-bit Photometrics Cool Snap FX camera by the Micro-Manager software. Pictures were edited with the Fiji software ([@bib55]). The Cell Counter Fiji plugin was used for quantification of pathological features and histological markers.

RNA extraction and analysis {#s16}
---------------------------

RNA was isolated from DLP and anterior prostate samples, and quantitative PCR of retrotranscribed RNAs were performed as described ([@bib26]). Primer sequences were as follows: p16 forward: 5′-GAACTCTTTCGGTCGTACCC-3′, reverse: 5′-CAGTTCGAATCTGCACCGTA-3′; p19^ARF^ forward: 5′-GCTCTGGCTTTCGTGAACAT-3′, reverse: 5′-GTGAACGTTGCCCATCATC-3′; p21 forward: 5′-TCTTCTGCTGTGGGTCAGGAG-3′, reverse: 5′-GAGGGCTAAGGCCGAAGATG-3′; IL-1α forward: 5′-AGACGGCTGAGTTTCAGTGAG-3′, reverse: 5′-TAAGGTGCTGATCTGGGTTG-3′; IL-1β forward: 5′-ACGACAAAATACCTGTGGCC-3′, reverse: 5′-TGGGTATTGCTTGGGATCCA-3′; M-CSF forward: 5′-GACCCAGGATGAGGACAGAC-3′, reverse: 5′-TTCCCATATGTCTCCTTCCA-3′; TNFα forward: 5′-CACTTGGTGGTTTGCTACGA-3′, reverse: 5′-CCCCAAAGGGATGAGAAGTT-3′; IL-1rn forward: 5′-TGAGCTGGTTGTTTCTCAGG-3′, reverse: 5′-GAAAAGACCCTGCAAGATGC-3′; Ly6c forward: 5′-ATAGCACTCGTAGCACTGCA-3′, reverse: 5′-ACCTTGTCTGAGAGGAACCC-3′; Ly6g forward: 5′-TGTGCTCATCCTTCTTGTGG-3′, reverse: 5′-AGGGGCAGGTAGTTGTGTTG-3′; CD11b forward: 5′-CAAAGAACAACACACGCAGG-3′, reverse: 5′-GGCTCCCCAACCAGTGTATA-3′; CKIε forward: 5′-TGAAGCATGGAGTTGCGTGT-3′, reverse: 5′-TGTTGGCACCCAGGTAGATG-3′; CKIα1 forward: 5′-TCCGCATCCTTTTCAGGACC-3′, reverse: 5′-AGAAACCTGTGGGGGTTTGG-3′; CKIδ forward: 5′-TACCTCACACACGGCCAACA-3′, reverse: 5′-GCAGCCGCATACTCACTTTC-3′; CKIγ1 forward: 5′-GGGTGGTTGAGAGAAGCAGT-3′, reverse: 5′-CCTGTCCTCCTAAATCAGCGG 3′; CKIγ2 forward: 5′-GCTATCAAGCTGGAGCCCAT-3′; reverse: 5′-TAGTAGACCTGAGGGACGCC 3′; CKIγ3 forward: 5′-TGGCAAGGCTTAAAGGCTGA-3′; reverse: 5′-TGGGAAGTTCTCACACAACACT-3′; 18S forward: 5′- TCGTCTTCGAAACTCCGACT-3′, reverse: 5′-CGCGGTTCTATTTTGTTGGT-3′.

Preparation and analysis of prostate tissue protein extracts {#s17}
------------------------------------------------------------

Prostates were crushed in ice-cold modified radioimmunoprecipitation assay buffer (50 mM Tris, pH 7.5, 1% Nonidet P40, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 5 mM EDTA, 5% glycerol, supplemented with protease inhibitor cocktail \[05892970001; Sigma-Aldrich\], PhoSTOP \[PHOSS-RO; Sigma-Aldrich\] and 1,4-dithiothreitol 10 mM) with a potter. Protein extracts (25 µg) were electrophoresed on 8--15% SDS-polyacrylamide gels and electroblotted to Hybond nitrocellulose membranes (Amersham Biosciences). Proteins were detected using primary antibodies directed against γH2AX (05-636; EMD Millipore; 1:1,000), AKT (4691; Cell Signaling Technology; 1:1,000), AKT pS473 (4060; Cell Signaling Technology; 1:1,000), and tubulin (TUB-2A2; IGBMC; 1:10,000). Membranes were probed with secondary HRP-conjugated secondary antibodies (Amersham Biosciences; 1:10,000), which were revealed using an enhanced chemiluminescence detection system (Pierce).

FACS analysis {#s18}
-------------

Fresh prostates were chopped with a scalpel blade immediately after dissection, and dissociated for 4 h in 1 ml/50 mg of prostate tissue of dissociation buffer (RPMI-1640 cell culture medium \[Thermo Fisher Scientific\] supplemented with 10% heat-inactivated FBS, Hepes, pH 7.2, 10 mM, 200 µg/ml hyaluronidase \[H3506; Sigma-Aldrich\], 2.5 mg/ml collagenase \[C0130; Sigma-Aldrich\], and 25 mM CaCl~2~) at 37°C with gentle shaking. After centrifugation (400 *g*; 5 min), pellets were washed twice with 10 ml of PBS and resuspended in 2 ml of prewarmed 0.05% trypsin (Thermo Fisher Scientific) supplemented with 5 mM EDTA. After a 5 min incubation at 37°C with gentle shaking, trypsin was inactivated by addition of RPMI-1640 supplemented with 10% heat-inactivated FBS, Hepes, pH 7.2, 10 mM, and 300 µg/ml DNase I (DN25; Sigma-Aldrich). Remaining cell clumps were physically dissociated by 10 passages through an 18-G needle and 10 passages through in a 20-G needle. After filtration on a 40-µm cell strainer, cell suspensions were centrifuged at 400 *g* for 5 min, washed twice in ice-cold PBS, and resuspended in FACS buffer (PBS supplemented with 5 mM EDTA and 1% heat-inactivated FBS).

Cells were incubated with anti-CD16/32 antibodies (BD PharMingen; 1:50) for 15 min on ice to block nonspecific binding sites to Fc receptors, stained with antibodies directed against Epcam (PE-Cy7; Biolegend), CD45 (PerCP-Cy5.5; eBiosciences), CD11b (BV421; BD biosciences), and GR1 RB6-8C5 (FITC; eBiosciences; 1:50 each) for 15 min on ice, and analyzed on a BD LSR II Flow Cytometer (IGBMC; cytometry service) with FlowJo software. The presence of GR1-positive cells was determined by gating CD11b^high^GR1^high^ cells in Epcam^low^CD45^high^ cells. The proportion of CD11b^high^GR1^high^ cells was determined as the number of CD11b^high^GR1^high^ relative to the total number of single cells of dissociated prostate cells that were analyzed.

Statistical analysis {#s19}
--------------------

Statistical analysis was performed with the one-way ANOVA test with Prism (GraphPad).

Online supplemental material {#s20}
----------------------------

Fig. S1 shows the generation and characterization of PTEN^(i)pe−/−^ mice. Fig. S2 shows pHP1γ immunodetection in PEC of PTEN^(i)pe−/−^ mice. Fig. S3 shows DDR marker immunodetection of in PEC of PTEN^(i)pe−/−^ mice. Fig. S4 shows p53 expression PEC of PTEN^(i)pe−/−^ mice and efficient ablation of p53 in PTEN/p53^(i)pe−/−^ mice. Fig. S5 shows CKIα1, -δ, -γ1, -γ2 and -γ3 transcript levels in the prostate of PTEN^(i)pe−/−^, and control mice at various time points after gene ablation.
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